Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Shouse

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Cancers|March 29, 2023
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell LymphomaColton Ladbury, Savita Dandapani, Claire Hao, et al.
Research Square|May 18, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaAlexey Danilov, Sonia Rodriguez-Rodriguez, Dan Vuong, et al.
Annals of Surgery|July 13, 2026
Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort StudyHamza Mohammed, Muhammad Talha Waheed, Vijay Trisal, et al.
Haematologica|July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trialGeoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Haematologica|July 18, 2024
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaTamer Othman, Paul Frankel, Pamela Allen, et al.
Leukemia & Lymphoma|August 6, 2025
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphomaAnnie Xiao, Lu Chen, Stacy Pak, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
Blood Cancer Journal|October 18, 2024
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort studyNatalie S Grover, Kaitlin Annunzio, Marcus Watkins, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Cancers|March 29, 2023
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell LymphomaColton Ladbury, Savita Dandapani, Claire Hao, et al.
Research Square|May 18, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaAlexey Danilov, Sonia Rodriguez-Rodriguez, Dan Vuong, et al.
Annals of Surgery|July 13, 2026
Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort StudyHamza Mohammed, Muhammad Talha Waheed, Vijay Trisal, et al.
Haematologica|July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trialGeoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Haematologica|July 18, 2024
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaTamer Othman, Paul Frankel, Pamela Allen, et al.
Leukemia & Lymphoma|August 6, 2025
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphomaAnnie Xiao, Lu Chen, Stacy Pak, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
Blood Cancer Journal|October 18, 2024
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort studyNatalie S Grover, Kaitlin Annunzio, Marcus Watkins, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Pageof 6